Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
By Colin Kellaher
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study.
Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.
The companies said they plan to share data from the study with global regulatory authorities.
Lung cancer is the leading cause of cancer death around the world, with non-small cell lung cancer accounting for more than 80% of all cases, and EGFR-activating mutations occurring in 14% to 38% of non-small cell lung cancer tumors.
Merck and Daiichi Sankyo last year agreed to jointly develop and commercialize a trio of antibody-drug conjugates, including patritumab deruxtecan, in a deal worth up to $22 billion. The companies last month added MK-6070, the key drug candidate from Merck's recent purchase of Harpoon Therapeutics, to the collaboration.
Merck, based in Rahway, N.J., and Japan's Daiichi Sankyo are studying Patritumab deruxtecan as both a monotherapy and in combination with other therapies in a global development program across a range of cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 17, 2024 06:44 ET (10:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying